玻璃体腔注射Bevacizumab联合PDT治疗CSC  

Analysis on Bevacizumab with PDT for CSC

作　　者：杨敏 姜旭光 李燕龙 韩晓冬 Min Yang;Xu-Guang Jiang;Yan-Long Li;Xiao-Dong Han(Department of Fundus Diseases,Xi'an Aier Ancient City Eye Hospital,Xi'an 710000,Shaanxi Province,China)

机构地区：[1]西安爱尔古城眼科医院眼底病科,中国陕西省西安市710000

出　　处：《国际眼科杂志》2018年第5期883-886,共4页International Eye Science

摘　　要：目的:研究玻璃体腔注射bevacizumab联合PDT治疗中心性浆液性视网膜脉络膜病变(central serous choroiretinopathy,CSC)患者的临床疗效。方法:选取2012-02/2015-04于我院就诊的CSC患者82例82眼作为研究对象,所有患者均经OCT、FFA确诊,且均为单眼患病。按治疗方法不同将所有患者分为对照组35例35眼和研究组47例47眼。其中对照组患者采用光动力(PDT)治疗,研究组患者采用PDT联合玻璃体腔内注射bevacizumab治疗。对比两组患者治疗次数、浆液性色素上皮脱离(PED)平伏率和黄斑视网膜下液、黄斑中心区直径的总体积、黄斑中心区直径6mm的平均厚度和黄斑中心区1mm范围的厚度等OCT指标,以及治疗前后不同时间最佳矫正视力和临床疗效。结果:对照组患者中32眼治疗1次,3眼治疗2次,平均治疗次数为1.25±0.20次;研究组中9眼治疗3次,10眼治疗2次,28眼治疗1次,平均治疗次数1.48±0.22次。两组患者治疗次数对比差异无统计学意义(t=1.209,P>0.05)。对照组患者PED平伏13眼(37%),黄斑视网膜神经上皮下浆液吸收22眼(63%)。研究组患者PED平伏30眼(64%),黄斑视网膜神经上皮下浆液吸收17眼(36%)。两组患者治疗后PED平伏率和黄斑视网膜神经上皮下浆液吸收率对比均差异均有统计学意义(P<0.05)。两组患者治疗前黄斑中心区直径的总体积、黄斑中心区直径6mm的平均厚度和黄斑中心区1mm范围的厚度等OCT指标对比差异无统计学意义(P>0.05),而治疗后研究组患者在这些OCT指标上均明显低于对照组,且差异均有统计学意义(P<0.05)。两组患者治疗后在这些OCT指标均明显低于各组治疗前,且均有统计学意义(P<0.05)。两组患者治疗前和治疗后1mo最佳矫正视力对比差异无统计学意义(P>0.05),治疗后3、6mo时研究组患者最佳矫正视力(LogM AR)明显低于对照组,且差异均有统计学意义(P<0.05)。对照组患者中无效6眼,好转15眼,显效8眼,治愈6眼,�AIM:To study the influence of intravitreal injection of bevacizumab combined with photon dynamic treatment(PDT)in the treatment of central serous choroiretinopathy(CSC).METHODS:We selected 82 CSC patients treated in the hospital between February 2012 and April 2015,who were diagnosed by optical coherence tomography(OCT)and fundus fluorescein angiography(FFA)and all got the disease monocularly,and divided them into two groups called control group(n=35)and research group(n=47)by different methods,the patients of control group were treated by PDT method,while the patients of research group were treated by vitreous bevacizumab injection combined with PDT.Then compare the number of treatment times,the rate of flat pigment epithelial detachment(PED),macular subretinal fluid absorption,OCT indexes such as volume of the macular central hub,average thickness of central macular with diameter of 6mm and thickness of central macular region below 1mm range,the difference of corrected vision and clinical efficacy of two groups before and after the treatment.RESULTS:There were 32 eyes which were treated once,and 3 eyes which were treated twice in the control group,the average treatment times was 1.25±0.20;however,there were 9 eyes which were treated three times,10 eyes twice,28 eyes once,the average treatment number was 1.48±0.22,the treatment times of two groups had no statistical difference(t=1.209,P>0.05).On the other hand,13 eyes'PED(37%)was flat in the control group,22 eyes(63%)which macular retinal subepithelial serous absorption;30 eyes'PED(64%)was flat in the research group,17 eyes(36%)which macular retinal subepithelial serous absorption.The rate of flat PED and macular retinal subepithelial serous absorption of two groups had obvious statistical difference(P<0.05).The OCT indexes such as volume of the macular central hub,average thickness of central macular with diameter of 6mm and thickness of central macular region bellow 1mm of two groups had no statistical difference before the treatment(P>0.05),in contrast thes

关 键 词：中心性浆液性视网膜脉络膜病变 玻璃体腔注射 BEVACIZUMAB 光动力 临床疗效 

分 类 号：R773.4[医药卫生—眼科]